Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

High-sensitivity versus conventional troponin in assessing PE risk

Clinical question: Is high-sensitivity cardiac troponin I (hs-cTnI) better at predicting outcomes for hemodynamically stable pulmonary embolism (PE) than conventional cardiac troponin I (cTnI)?

Background: Hs-cTnI is more sensitive compared to cTnI, but traditional PE risk scores rely on cTnI.

Study design: Multicenter cohort study

Setting: 12 hospital emergency departments in Spain

Synopsis: In post-analysis of the PROTECT study of 834 hemodynamically stable PE patients, 139 patients (16.7%) had a positive cTnI versus 264 hs-cTnI patients (31.7%). A complicated course (hemodynamic collapse, recurrent PE, or 30-day mortality) occurred in 62 patients (7.4%; 95% CI, 5.7-9.4). Hs-cTnI as a binary variable was not associated with significantly increased odds of a complicated course (odds ratio [OR], 1.12; (95% CI, 0.65-1.93) as compared to cTnI (OR, 2.84; 95% CI, 1.62-4.98). None of the 125 patients who had elevated hs-cTnI with normal cTnI developed a complicated course.

Using the European Society of Cardiology 2019 risk stratification and cTnI, 247 patients (29.6%) were designated as low-risk. Within this group, 78 (31.6%) had a positive hs-cTnI, but none had a complicated course.

Bottom line: In patients with stable PEs, hs-cTnI overestimated the 30-day risk of mortality and did not change risk stratification.

Citation: Bikdeli B, Muriel A, et al. High-sensitivity vs conventional troponin cutoffs for risk stratification in patients with acute pulmonary embolism. JAMA Cardiol. 2024;9(1):64-70.

Dr. Kochar

Dr. Kochar

Dr. Kochar is a hospitalist in the department of hospital medicine at Mount Sinai Hospital, and an assistant professor of medicine at the Icahn School of Medicine in New York.

  • High-sensitivity versus conventional troponin in assessing PE risk

    June 3, 2024

  • Limited utility in using NT-proBNP rather than functional capacity to estimate risk of perioperative MACE

    June 3, 2024

  • Semaglutide reduces major adverse cardiovascular events by 20% in patients with cardiovascular disease

    June 3, 2024

  • Comparing in-hospital adverse events in elderly postoperative delirium patients: haloperidol versus atypical antipsychotics

    June 3, 2024

  • Hydrocortisone reduces mortality in severe CAP

    June 3, 2024

  • SHM 2024 Awards of Excellence and Junior Investigator Award

    June 3, 2024

  • Celebrating the 2023 Chapter Excellence Status Awards Recipients

    June 3, 2024

  • Aiming for Equitable Care for Transgender Patients

    June 3, 2024

  • Facing the Inevitable: Cyberattacks in Healthcare

    June 3, 2024

  • Chapter Spotlight: Pee Dee

    June 3, 2024

1 … 43 44 45 46 47 … 984
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • Cookie Preferences